Experienced in Bronchiectasis

Satoshi Okada

Minami, JP 
Experienced in Bronchiectasis
Minami, JP 
OverviewLocationsClinical Research

Overview

Satoshi Okada practices in Minami, Japan. Mr. Okada is rated as an Experienced expert by MediFind in the treatment of Bronchiectasis. His top areas of expertise are Hyper IgE Syndrome, Autosomal Dominant Hyper IgE Syndrome, Infantile Neutropenia, Bone Marrow Transplant, and Splenectomy.

His clinical research consists of co-authoring 241 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Bronchiectasis.

Gender
Male

Locations

Minami, Japan
Other Locations
Hiroshima, Japan
Okayama, Japan
Nagoya, 4648601, Japan
Meguro, 1528550, Japan
Sugano, 2728513, Japan
Tokyo, Japan
Kurashiki, 7100046, Japan
Ichikawa, Japan
Kashiwa, Japan
Osaka, Japan
Kasai, 6752103, Japan
Chiba, Japan
Asahimachi, 5458585, Japan
Ino, Japan
Suita, 5650871, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS
A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS
Enrollment Status: Terminated
Publish Date: July 10, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

241 Total Publications

Chemogenetic activation of the medial prefrontal cortex alleviates the impaired extinction of fear memory through the increase in the binding of EGR1 and TET1 in an animal model of PTSD.
Chemogenetic activation of the medial prefrontal cortex alleviates the impaired extinction of fear memory through the increase in the binding of EGR1 and TET1 in an animal model of PTSD.
Journal: Psychopharmacology
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Okada's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 102 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile